CTD Holdings Inc. (CTDH) news stock charts
CTD Holdings Inc. (CTDH/CTDH.OB) Investment Summary:
CTD Holdings, Inc. engages in the marketing and sale of cyclodextrins and related products. The company develops cyclodextrins-based applications in stabilization of flavors for food products; preparation of antifungal complexes for foods and toiletries; elimination of undesirable tastes and odors; stabilization of fragrances and dyes; reduction of foaming in foods; cosmetics and toiletries; and the improvement of quality, stability, and storability of foods. It also manufactures selected cyclodextrin complexes, as well as distributes cyclodextrins. CTD Holdings sell cyclodextrins, the molecules that bring oil and water together for applications in the areas of agriculture, analytical chemis...www.cyclodex.com
5 Employees
Founded in 1990
CTD HOLDINGS INC (CTDH:OTC BB)
LAST $0.07 USD
CHANGE TODAY +0.01 16.67%
VOLUME 45.7K
As of 8:10 PM 09/3/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of CTD HOLDINGS INC (CTDH)
|
OPEN
$0.06
|
PREVIOUS CLOSE
$0.06
|
|
|
DAY HIGH
$0.07
|
DAY LOW
$0.06
|
|
|
52 WEEK HIGH
03/22/10 - $0.24
|
52 WEEK LOW
09/28/09 - $0.05
|
|
|
MARKET CAP
2.3M
|
AVERAGE VOLUME 10 D
17.2K
|
|
|
EPS TTM
$-0.01
|
SHARES OUTSTANDING
33.4M
|
|
|
CTDH Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for CTD HOLDINGS INC (CTDH)
CTD Holdings Inc. expected to report Q3 2010 results on November 12, 2010. This event was calculated by Capital IQ (Created on August 31, 2010).
08/31/2010
CTD Holdings Inc. expected to report Q3 2010 results on November 12, 2010. This event was calculated by Capital IQ (Created on August 31, 2010).
CTD Holdings Inc. Appoints Jeffrey L. Tate to the Board of Directors
08/17/2010
On August 17, 2010, CTD Holdings Inc. appointed Jeffrey L. Tate, Ph.D., to the Company's Board of Directors. Dr. Tate has been President and Chief Operating Officer of NanoSonic Products Inc., a wholly-owned subsidiary of the Company responsible for the Company's product Aquaplex, since February 2010.
CTD Holdings Inc. expected to report Fiscal Year 2010 results on March 30, 2011. This event was calculated by Capital IQ (Created on June 27, 2010).
06/27/2010
CTD Holdings Inc. expected to report Fiscal Year 2010 results on March 30, 2011. This event was calculated by Capital IQ (Created on June 27, 2010).
CTD Holdings Inc. financial resources
CTDH Competitors
| Company | Last | Change | |
| No competitor information is available for CTDH. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | CTDH | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.5x |
|
| Price/Book | 1.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.1x |
|
|
CTDH |
||
|
CTDH transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About CTD Holdings Inc.
CTD HOLDINGS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
2010-08-18 05:44:44
Quote: Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On August 17, 2010, CTD Holdings, Inc. (the "Company") appointed Jeffrey L.
Tate, Ph.D., age 52, to the Company's Board of Directors (the "Board").
Dr. Tate has been President and Chief Operating Officer of NanoSonic Products,
Inc. ("NSP"), a wholly-owned subsidiary of the Company responsible for the
Company's...Read article
CTD HOLDINGS INC Files SEC form 10-Q, Quarterly Report
2010-08-16 09:49:22
Quote: Management's Discussion and Analysis of Financial Condition and Results
of Operations.
Introduction
CTD Holdings, Inc. (referred to as the "Company," "CTD" or in the first person
notations of "we," "us," and "our") began operations in 1990. Our revenues are
principally derived from retail sales of cyclodextrins and cyclodextrin
complexes. Our sales are primarily to major chemical supply houses around the
world, pharmaceutical companies, and ...Read article
Trappsol(R) Cyclo(TM) Awarded Orphan Drug Status
2010-06-02 10:00:53
Keywords: Trappsol(R) Cyclo(TM) Awarded Orphan Drug Status, cdj.f,ctdh.ob
Quote: CTDHNewsCDJNews) today confirmed that CTD's, Trappsol® Cyclo™, has been awarded orphan drug status for the treatment of Niemann Pick Type C (NPC) disease by the U.S. FDA in a letter received by Dr. Caroline Hastings of the Children's Hospital Oakland Research Institute (CHORI). Dr. Hastings and Chris Hempel have used CTD's technical input very effectively with the FDA to, first, craft the compassionate use approval almost two years ago, and now, achieve the awarding of orphan drug statu...Read article
CTD HOLDINGS INC Files SEC form 10-Q, Quarterly Report
2010-05-17 03:32:13
Quote: Management's Discussion and Analysis or Plan of Operation.
Introduction
CTD Holdings,Inc.(referred to as the "Company," "CTD" or in the first person
notations of "we," "us," and "our") beganoperations in 1990.Our revenues are
principallyderivedfromretailsalesofcyclodextrinsandcyclodextrin
complexes.Our sales are primarily to majorchemicalsupply houses around the
world, pharmaceutical companies, and food companies for research and development
a...Read article
CTD Holdings, Inc. Introduces NanoSonic Products, a Subsidiary to European Union
2010-04-13 03:18:35
Quote: CTDHNewsCDJNews) introduces NanoSonic Products, a subsidiary to Europe.Dr. Jeffrey Tate (Pres/COO of NSP) has been invited to present at the biennial International Cyclodextrin World Symposium in Vienna, Austria this May.Dr. Tate will show both the scientists and the industrialists at the symposium in his presentation that the combination of Pulse Combustion Drying (PCD) and CD's will rectify the historical supply and demand anomalies of the CD industry; and at the same time assure pharmaceutica...Read article
CTD Holdings, Inc. Announces Fiscal 2009 Results and Outlook for 2010
2010-04-08 03:31:00
Quote: CTDHNewsCDJNews) announced today its fiscal year results for 2009.CTD Holdings posted higher revenue for 2009 over 2008 largely due to a newly introduced product, Trappsol Cycloâ„¢. Revenue was $623,874, a 26.3% improvement from the 2008 comparable period. Shareholders' equity increased 5.5% not reflecting the share repurchase program implemented during fiscal year 2009. Net income improved from a net loss of ($413,232) in 2008 to ($193,127) in 2009. Operating cash flow improved 67% to $108,...Read article
CTD Holdings, Inc. Formalizes International Sales of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Type C (NPC)
2010-04-06 07:56:35
Quote: CTDHNewsCDJNewsLebanonJapan. "We are monitoring the results of these interventions and continue to supply larger amounts of Cyclo™ to the requesting medical facilities as they implement the AddiandCassi protocol," stated CEO, Rick Strattan. He continued, "The Company expects significant growth in its international sales of the Cyclo™ product line in 2010."www.Addiandcassi.com) had their orphan drug application accepted by the US FDA for Trappsol® Cyclo™ to treat NPC.NPC is o...Read article
CTD Holdings Receives Large Order From Brazil for Trappsol Cyclo(TM) Which May Provide Benefit in Many Lysosomal Storage Diseases
2010-04-06 07:56:34
Quote: CTDHNewsCDJNews) today announced that a significant order has been placed by a Brazilian healthcare organization for Trappsol Cycloâ„¢ for the experimental treatment of Niemann Pick Type C (NPC) disease. Currently, there are approximately a dozen children in Brazil diagnosed with NPC disease, a rare genetic cholesterol transport disorder that causes severe neurological effects in infants, children and adults."There is no known cure for Niemann Pick Type C disease, nor is there any FDA approv...Read article
CTD Holdings, Inc. Announces Fiscal 2009 Results and Outlook for 2010
2010-04-06 07:56:32
Quote: CTDHNewsCDJNews) announced today its fiscal year results for 2009.CTD Holdings posted higher revenue for 2009 over 2008 largely due to a newly introduced product, Trappsol Cycloâ„¢. Revenue was $623,874, a 26.3% improvement from the 2008 comparable period. Shareholders' equity increased 5.5% not reflecting the share repurchase program implemented during fiscal year 2009. Net income improved from a net loss of ($413,232) in 2008 to ($193,127) in 2009. Operating cash flow improved 67% to $108,...Read article
CTD HOLDINGS INC Files SEC form 10-K, Annual Report
2010-04-01 03:40:19
Quote: Management's Discussion and Analysis or Plan of Operation.
Introduction
CTD Holdings,Inc. beganoperations in 1990. Our revenues are principally
derived from the resale of cyclodextrins and cyclodextrincomplexes.Our sales
are primarily to major chemicalsupply houses around the world,pharmaceutical
companies,foodcompaniesfor researchanddevelopmentand todiagnostics
companies.We acquire our productsprincipally from outside the United States,
largely from Japan and Hungary,but are gradually findin...Read article
CTD Holdings Announces Agreement to Dividend Shares of ViStra Growth Partners to Shareholders
2010-04-01 03:40:19
Quote: CTDHNewsCDJNews) today announced that it has agreed to dividend shares that it owns of ViStra Growth Partners to shareholders of stock in CTD Holdings, Inc.On December 31, 2009, CTD Holdings ("CTD", or the "Company") agreed to transfer 81% of its holdings in ViStra Growth Partners, Inc. ("ViStra") to Louis S. Weltman, the Chief Executive Officer of ViStra, in exchange for the fees owed VGP for the legal, accounting and negotiating, services provided in the 2009 negotiations that resulted in the ...Read article
CTD Holdings Announces Agreement to Dividend Shares of ViStra Growth Partners to Shareholders
2010-03-30 06:46:23
Quote: CTDHNewsCDJNews) today announced that it has agreed to dividend shares that it owns of ViStra Growth Partners to shareholders of stock in CTD Holdings, Inc.On December 31, 2009, CTD Holdings ("CTD", or the "Company") agreed to transfer 81% of its holdings in ViStra Growth Partners, Inc. ("ViStra") to Louis S. Weltman, the Chief Executive Officer of ViStra, in exchange for the fees owed VGP for the legal, accounting and negotiating, services provided in the 2009 negotiations that resulted in the ...Read article
CTD Holdings Receives Large Order From Brazil for Trappsol Cyclo(TM) Which May Provide Benefit in Many Lysosomal Storage Diseases
2010-03-23 06:40:55
Quote: CTDHNewsCDJNews) today announced that a significant order has been placed by a Brazilian healthcare organization for Trappsol Cycloâ„¢ for the experimental treatment of Niemann Pick Type C (NPC) disease. Currently, there are approximately a dozen children in Brazil diagnosed with NPC disease, a rare genetic cholesterol transport disorder that causes severe neurological effects in infants, children and adults."There is no known cure for Niemann Pick Type C disease, nor is there any FDA approv...Read article
CTD Holdings, Inc. Formalizes International Sales of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Type C (NPC)
2010-03-15 08:15:55
Quote: CTDHNewsCDJNewsLebanonJapan. "We are monitoring the results of these interventions and continue to supply larger amounts of Cyclo™ to the requesting medical facilities as they implement the AddiandCassi protocol," stated CEO, Rick Strattan. He continued, "The Company expects significant growth in its international sales of the Cyclo™ product line in 2010."www.Addiandcassi.com) had their orphan drug application accepted by the US FDA for Trappsol® Cyclo™ to treat NPC.NPC is o...Read article
CTD Holdings, Inc. Reorganizes Structure to Better Emphasize Branded Products, Trappsol(R) and Aquaplex(R)
2010-03-10 01:24:24
Quote: CTDHNewsCDJNewsU.S. Food and Drug Administration for Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin) in the treatment of Niemann Pick Type C disease.Niemann Pick Type C disease is a rare, fatal illness caused by a genetic mutation, which prevents cholesterol and other lipids from properly metabolizing within the cell. As a result, dangerous amounts of cholesterol accumulate in the liver and spleen and ultimately the brain. Although rare, Niemann Pick Type C disease has generated enor...Read article
CTD Holdings, Inc. Reorganizes Structure to Better Emphasize Branded Products, Trappsol(R) and Aquaplex(R)
2010-03-09 08:45:07
Quote: CTDHNewsCDJNewsU.S. Food and Drug Administration for Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin) in the treatment of Niemann Pick Type C disease.Niemann Pick Type C disease is a rare, fatal illness caused by a genetic mutation, which prevents cholesterol and other lipids from properly metabolizing within the cell. As a result, dangerous amounts of cholesterol accumulate in the liver and spleen and ultimately the brain. Although rare, Niemann Pick Type C disease has generated enor...Read article
CTD Holdings, Inc. Names President of Newly Formed Subsidiary
2010-03-01 04:19:27
Quote: CTDHNewsCDJNews) announces the installation of Dr. Jeffrey Tate as the President/COO of NanoSonic Products, Inc. ("NSP"), a new, wholly owned subsidiary.Dr. Tate, former President of J. Jireh Products, LLC, has begun planning for the company's acquisition of a new Pulse Dryer system to be installed at CTD's 40 acre facility in High Springs, Florida. "Dr. Tate has 18 years of experience with the development of products surrounding the utilization of Pulse Drying technologies," stated CEO and Chai...Read article
CTD Holdings, Inc. Names President of Newly Formed Subsidiary
2010-02-18 06:11:11
Quote: CTDHNewsCDJNews) announces the installation of Dr. Jeffrey Tate as the President/COO of NanoSonic Products, Inc. ("NSP"), a new, wholly owned subsidiary.Dr. Tate, former President of J. Jireh Products, LLC, has begun planning for the company's acquisition of a new Pulse Dryer system to be installed at CTD's 40 acre facility in High Springs, Florida. "Dr. Tate has 18 years of experience with the development of products surrounding the utilization of Pulse Drying technologies," stated CEO and Chai...Read article
CTD Holdings Announces Second Quarter Results
2010-01-29 01:34:57
Quote: CTDHNewsCDJNews) announced today its second quarter results of operations.Net Operating Loss decreased 36.7% and product sales increased 6.9% to
almost $245,000 for the first six months of 2009 compared to the same
period in 2008."Although profit and loss have not been emphasized by management in the
past because the dollar amounts were always small, it's nice to see both
going in the right direction. Third quarter sales have gotten off to a
great start already," stated Rick Strattan, Chairman/C...Read article
CTD Holdings, Inc. Announces Profitable 3rd Quarter Results
2010-01-29 01:34:56
Quote: CTDHNewsCDJNews) announced today its third quarter results of operations.CTD Holdings posted net income for the third quarter of $32,735 and reduced
its total nine month loss to ($34,871) vs. ($74,606) in 2008, a 53.3%
improvement. Revenue increased 51.5% for the three months ended September
30, 2009 vs. the September 30, 2008 period. Overall revenue for the nine
months ended September 30, 2009 increased 24% to $460,277 vs. $371,230 for
the comparable 2008 period. Working capital increased 21.4%...Read article
Would you like to leave a comment about CTD Holdings Inc. CTDH/CTDH.OB
Find out what social network information about CTD Holdings Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides CTD Holdings Inc.'s Stock there is more great penny stock and market information at Realpennies